Skip to main content

Market Overview

Cellectis, Cytovia Therapeutics Ink Gene-Edited Therapy Pact For Oncology Indications

  • Cytovia Therapeutics Inc and Cellectis SA (NASDAQ: CLLS) have entered into a strategic research and development collaboration to develop TALEN gene-edited induced pluripotent stem cells (iPSC) Natural Killer (NK) and Chimeric Antigen Receptor (CAR)-NK cells.
  • Cellectis will receive up to $760 million in milestone payments from Cytovia for the first five TALEN gene-edited iPSC-derived NK products. It will also receive single-digit royalty payments on the net sales. 
  • Cellectis will receive an equity stake of $15 million in Cytovia stock or an upfront cash payment of $15 million if certain conditions are not met by December 31, 2021, as well as an option to invest in future financing rounds. 
  • The agreement utilizes Cellectis' gene-editing technology, TALEN, to yield NK and CAR-NK treatments with improved potency, persistence, and safety for various cancers, including solid tumors. Cytovia's CAR-NKs are expected to enter clinical trials by 2022.
  • Cellectis will develop custom TALEN, Cytovia will conduct the pre-clinical evaluation, clinical development, and commercialization of the selected therapeutic candidates. Cytovia will have the worldwide license to its TALEN.
  • Price Action: CLLS moves 9.2% higher at $29.66 in premarket trading on the last check Tuesday.

Related Articles (CLLS)

View Comments and Join the Discussion!

Posted-In: Gene EditingBiotech News Small Cap General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at